ISDS Case Map
intellectual property
The Thai government's showdown with multinational drug companies over compulsory licensing could result in a downgrade on Washington's watch list of countries with poor intellectual property (IP) rights protection, trade sources say.
The Japan-Philippines Economic Partnership Agreement poses serious questionable intellectual property provisions which ultimately undermine the rights of Filipino farmers, communities and the public in general.
This South Centre policy brief examines the approach under the ongoing EPA negotiations with respect to innovation, biodiversity and traditional knowledge, public health, Least Developed Countries and on enforcement of intellectual property rights. It concludes that considering the level of economic development in ACP countries, the negotiations should not include IP rights as part of the partnership agreement.
This paper addresses the main threats of the intellectual property chapters in the
bilateral and regional agreements with the US for access to
medicines, give an overview of the reactions from different sectors to these agreements,
and outline some strategic considerations for future action.
A CIEL discussion paper on the European Union's attempts to impose TRIPS-plus standards on 76 African, Caribbean and Pacific countries
Malaysia has set some conditions in agreeing to the U.S. request for data exclusivity (DE) for new pharmaceutical products in the bilateral free trade agreement (FTA) negotiations, Health Minister Datuk Seri Dr Chua Soi Lek said today.
President Karachi Chamber of Commerce and Industry Majyd Aziz has called for creating awareness of intellectual property rights and effective enforcement of IPR legislation in order to attract investment in the country.
This is an English translation of a full study done in Colombia of the impacts of its US free trade agreement (FTA) on medicine consumption and the Colombian generic industry. The study study used the World Health Organization's methodology.
Opponents of the draft Japan-Thailand Economic Partnership Agreement (JTEPA) have asserted that the Surayud Chulanont government needs to take two controversial issues in the pact seriously.
The recent decisions of the Thai Ministry of Public Health to announce the Government Use of Patents on three patented drugs, i.e., Efavirenz (Stocrin®) of Merck Sharp and Dohme), Lopinavir+Ritonavir (Kaletra®) of Abbott Laboratory) and Clopidogrel (Plavix®) of Sanofi-Aventis), based on proposals from the National Health Security Office, have raised several questions among the public and also the concerned partners as well as the pharmaceutical industries, both in the country and internationally.
